Azenta, Inc. (AZTA) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Azenta (AZTA) through shares or fractional shares at any major US broker, or inside a life-science tools basket. Azenta stores biological samples for drug makers and runs GENEWIZ, a gene sequencing and synthesis business. Near $44.51 on November 20, 2026 (up about 33% year to date and 48% over one year), after a fiscal fourth quarter that beat estimates, it is a debt-free small-cap turnaround with an interim CEO and thin margins.
AZTA stock price
As of 2026-11-20, Azenta, Inc. (AZTA) last closed at $44.80, up 28.4% over the past year. Over the past 52 weeks it has traded between $16.02 and $48.90.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Azenta, Inc.'s investor relations page. Walnut is informational, not investment advice.
AZTA key stats
At $44.80 on November 20, 2026, Azenta, Inc. (AZTA) has a market cap of $1.9B. It next reports earnings around February 3, 2027 (estimated).
- Market cap
- $1.9B
- P/E (forward)
- 50.3
- Price to book
- 1.3
- Beta
- 1.47
- Next earnings
- around February 3, 2027 (estimated)
Market cap, P/E and yield are measured at the $44.80 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Azenta, Inc. (AZTA)?
The last two weeks for Azenta, Inc., as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- AZTA closed at $44.80 on November 20, 2026, down 1.9% over the past five trading days (from $45.65).
- Azenta, Inc. next reports quarterly results around February 3, 2027 (estimated).
- On November 11, 2026, Jefferies raised its target to $52.00 from $44.00 (Buy).
- On November 11, 2026, Needham raised its target to $57.00 from $37.00 (Buy).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Azenta, Inc. (AZTA) do?
Azenta, Inc., based in Burlington, Massachusetts, is what remains of Brooks Automation after it sold its semiconductor robotics business in 2022. It now has two segments. Sample Management Solutions (about $344 million of fiscal 2026 revenue) sells automated freezers and storage systems, cryogenic equipment, sample tubes and consumables, and runs repositories that store millions of biological samples for drug companies, biobanks and research groups. Multiomics (about $277 million) is GENEWIZ, which sells Sanger sequencing, next-generation sequencing and gene synthesis as a service. In July 2026 Azenta sold B Medical Systems, its vaccine cold-chain business, so it is now reported as discontinued.
Fiscal 2026, which ended September 30, was a hard year. Revenue from continuing operations rose about 5% to ~$622 million, but only about 2% organically. In May the company took a ~$149 million goodwill impairment on Multiomics, cut its outlook, and reported rework costs in its Automated Stores freezer line; the stock fell about 25% in a day. In August CEO John Marotta resigned and director Dr. Martin Madaus became interim CEO. The year ended better. On November 10 Azenta reported fourth-quarter revenue of ~$167 million (up 5%) and adjusted EPS of $0.28 against consensus near $0.11 to $0.12, and guided fiscal 2027 revenue to ~$648 million to $660 million with 200 to 250 basis points of adjusted EBITDA margin expansion. The shares rose about 20% the next day, to roughly $48.90, and closed near $44.51 on November 20, up about 22% over the month. Needham raised its target to $57 from $37 and kept a Buy rating.
The balance sheet is the steady part. Azenta ended the year with ~$506 million of cash and marketable securities and no debt, bought back 4.4 million shares for ~$118 million during fiscal 2026, and has ~$132 million left on its authorization. What it has not done is earn much: full-year adjusted EBITDA was ~$58 million, a 9.4% margin, and free cash flow was ~$27 million. At about $1.9 billion in market value, the stock prices in a margin recovery that management has promised before. The October deals with Elegen and SynPlexity, plus three North American lab closures, show where the company is placing its bets: gene synthesis grows, and Sanger sequencing shrinks.
What's driving Azenta, Inc. (AZTA)?
1. Margin recovery from cost cuts
The plan for fiscal 2027 depends mainly on costs. Azenta guided adjusted EBITDA margin up 200 to 250 basis points from 9.4%, which implies roughly 11.5% to 12% on ~$648 million to $660 million of revenue, or about $75 million to $79 million of adjusted EBITDA. The October restructuring closes three Multiomics lab sites in North America and is expected to save ~$11 million a year once complete by March 2027, on top of about $7 million from earlier fiscal 2026 actions. Management also guided free cash flow up about 25%. Fourth-quarter adjusted operating margin of 6.9% was up 120 basis points from a year earlier. Peers in life-science tools often run EBITDA margins above 20%, so even the guided level leaves a wide gap to close.
2. Gene synthesis replacing Sanger sequencing
Inside Multiomics, Sanger sequencing is declining as research moves to newer methods, and management said it trims about 4 points from the segment's organic growth and about 2 points from the company's. Fourth-quarter Multiomics revenue was flat at ~$73 million, down 1% organically. Gene synthesis grew, led by China. On October 28 Azenta licensed Elegen's cell-free gene synthesis technology on an exclusive, royalty-free basis (fixed license fees of $23 million, with a $25 million option to make it perpetual) and bought SynPlexity, a pooled gene library company, for $15 million plus up to $10 million in earnouts. Total capital for the Elegen deal is expected to be ~$32 million to $71 million. Management said the deals dilute fiscal 2027 margin by about 100 basis points.
3. Sample storage and repository services
Sample Management Solutions is the larger and steadier segment. Fourth-quarter revenue rose 9% to ~$94 million, or 4% organically, driven by Sample Repository Services and consumables and instruments, and helped by the acquisition of UK Biocentre, which added about 3 points to total company growth in the quarter. Repository contracts tend to be long and recurring, since moving millions of frozen samples is costly and risky for a customer. Automated Stores, the large automated freezer systems, was weaker because of customer capital constraints and quality rework that cost about $6 million in fiscal 2026. Management said bookings improved in the fourth quarter and that two new Automated Stores product lines are planned for the end of fiscal 2027.
4. Cash, buybacks and the next CEO
With ~$506 million in cash and securities and no debt, more than a quarter of Azenta's ~$1.9 billion market value is cash. The company repurchased 4.4 million shares in fiscal 2026, shrinking the count to roughly 43 to 44 million, and has ~$132 million left under a program that runs through 2028. That cash also pays for the Elegen and SynPlexity deals and the restructuring, which is expected to cost about $7 million in cash. Leadership is unsettled: Dr. Madaus has been interim CEO since August 22, 2026, and the earnings call did not update on a permanent search. Management is scheduled to present at the Evercore Healthcare Conference in December. The next CEO's choices on whether to keep both segments, spend cash on acquisitions or buy back more shares will shape the stock as much as quarterly results.
What are the risks to Azenta, Inc. (AZTA)?
Execution is the main risk. Azenta reaffirmed growth and margin targets in February 2026, then cut them in May alongside a $149 million impairment, and the stock fell about 25%. Guidance for fiscal 2027 asks for 3% to 5% organic growth and wider margins at the same time, under an interim CEO. Several law firms, including Rosen and Pomerantz, have announced investigations into possible securities claims tied to the May guidance cut and the August CEO resignation; as of early November 2026 no filed complaint was confirmed, but one could follow. Sanger sequencing keeps shrinking, and gene synthesis is crowded, with Twist Bioscience, IDT (part of Danaher) and GenScript all larger in the market. The Elegen license and SynPlexity purchase are early bets that cut margin first. Automated Stores sales depend on customers' capital budgets and on fixing the quality problems. China drove gene synthesis growth (China revenue rose 23% in fiscal 2026), which exposes the company to US-China trade and biotech policy. Lower NIH and academic funding and slower biotech spending would also weigh on demand. After a ~20% one-day rise and a gain of about 34% over three months, the shares carry high expectations into fiscal 2027, at about 50 times forward EPS estimates of $0.89.
What is the Azenta, Inc. (AZTA) forecast?
5 analysts publish price targets on AZTA, averaging $52.60 as of November 2026, or +17.4% against the $44.80 share price on November 20, 2026. The published targets run from $50.00 to $57.00, a narrow spread, and the ratings split 3 buy, 3 hold, 0 sell. Over the last six months there have been 4 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full AZTA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is AZTA a buy or a sell?
We give no verdict on Azenta, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Margin recovery from cost cuts. The plan for fiscal 2027 depends mainly on costs. The most optimistic published target, $57.00, assumes this works close to its best case.
The case against. Execution is the main risk. The most pessimistic target, $50.00, is roughly what AZTA is worth if this bites instead.
Read the full bull and bear case on AZTA, including what would have to change to break either one. Walnut is not an investment adviser.
How is Azenta, Inc. (AZTA) valued?
Market cap, P/E and dividend yield at today's price are in the AZTA key stats above. The business figures below come from Azenta, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (FY2026, continuing ops): ~$622 million (Q4 up ~5%)
- FY2027 revenue guidance: ~$648M to $660M
- Adjusted EBITDA margin (FY2026): ~9.4%
- Gross margin (FY2026): ~44%
- Cash and securities (Sept. 30, 2026): ~$506 million, no debt
- Market value (~$44.51 share price): ~$1.9 billion
As of November 2026: At ~$44.51 and roughly 43 to 44 million shares, Azenta's market value is about $1.9 billion, or about $1.4 billion after subtracting cash and securities. That is roughly 2.9 times fiscal 2026 revenue and about 2.2 times the midpoint of fiscal 2027 guidance after cash, and about 50 times the ~$0.89 of EPS analysts expect for fiscal 2027. GAAP results were a loss of $3.50 per share from continuing operations because of the impairment. Before the November report, MarketBeat showed a consensus Hold rating with an average target near $40 to $41; Yahoo Finance's five-analyst consensus now reads Buy with a mean target near $52.60, after Needham moved to $57.
Who competes with Azenta, Inc. (AZTA)?
Sample storage and management
In automated freezers, cold storage and sample consumables Azenta competes with Thermo Fisher Scientific, Hamilton Storage and Liconic, along with lab supply distributors such as Avantor. In outsourced biorepository services, rivals include Thermo Fisher's BioServices unit and specialist providers. Azenta's pitch is that it sells the equipment, the tubes and the long-term storage service together.
Gene synthesis
Twist Bioscience, Integrated DNA Technologies (owned by Danaher) and GenScript are the main rivals in synthetic genes and DNA fragments, and Twist in particular is growing fast in the same AI-driven drug discovery work Azenta is targeting with the Elegen and SynPlexity deals. Azenta's GENEWIZ brand is established, but its synthesis business is smaller than these competitors.
Sequencing services
For outsourced Sanger and next-generation sequencing, GENEWIZ competes with Eurofins Genomics, Psomagen, Plasmidsaurus, university core labs and many regional providers in the US, Europe and China. Lower-cost sequencing and in-house instruments from Illumina and others pressure pricing, which is part of why Sanger revenue keeps falling for Azenta.
What stocks are similar to Azenta, Inc. (AZTA)?
Other names that sit close to AZTA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Azenta, Inc. (AZTA)
There are three common ways to get AZTA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AZTA sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where AZTA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Azenta, Inc. (AZTA)
Azenta is a debt-free, roughly $1.9 billion life-science tools company in the middle of a turnaround: modest organic growth, thin margins, an interim CEO and a fresh push into gene synthesis after a volatile 2026 that ended with a strong fourth quarter and a rally to the top of its 52-week range.
More on Azenta, Inc. (AZTA)
Whether AZTA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AZTA a buy or a sell?, and where the stock could go from here in the AZTA stock forecast.
For income investors, whether AZTA pays a dividend and how the payout looks is covered in does AZTA pay a dividend? And to weigh AZTA against a peer, read the full side-by-side comparisons: AZTA vs TMO and AZTA vs AVTR.
Wondering how AZTA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Azenta, Inc.
Ask Walnut's AI anything about AZTA and see how it fits what you own.
FAQ
What does Azenta do?
+
Azenta sells tools and services that help drug companies, biotechs, hospitals and research labs store biological samples and analyze DNA. Its Sample Management Solutions segment makes automated freezer systems, cryogenic storage, sample tubes and racks, and runs repositories that hold samples for customers for years. Its Multiomics segment, sold under the GENEWIZ name, sequences DNA and synthesizes genes for researchers. In fiscal 2026, which ended September 30, the two segments brought in about $344 million and $277 million, for ~$622 million in total. Azenta used to be Brooks Automation, and it sold its semiconductor business in 2022 and its B Medical Systems vaccine cold-chain business in July 2026. It is headquartered in Burlington, Massachusetts, and trades on Nasdaq under AZTA.
Why did Azenta stock jump in November 2026?
+
The shares rose about 20% to roughly $48.90 on November 11, 2026, the day after fiscal fourth-quarter results. Adjusted EPS was $0.28, more than double consensus estimates of about $0.11 to $0.12, and revenue of ~$167 million beat the ~$160 million to $163 million expected. Management guided fiscal 2027 revenue to ~$648 million to $660 million, organic growth of 3% to 5%, adjusted EBITDA margin up 200 to 250 basis points, and free cash flow up about 25%. After a year that included a guidance cut, a $149 million impairment and a CEO resignation, investors read the quarter and outlook as evidence the turnaround is starting. The stock had traded below $20 in May 2026. By November 20 the shares had settled near $44.51, still about 22% higher for the month, and Needham lifted its price target to $57 from $37.
Is Azenta being acquired?
+
No acquisition of Azenta has been announced. Its most recent 8-K filings, through November 10, 2026, cover quarterly results, an October restructuring of its Multiomics labs, and two deals in which Azenta was the buyer: an exclusive license of Elegen's gene synthesis technology and the purchase of SynPlexity for $15 million plus up to $10 million in earnouts. Azenta has been a seller as well, completing the sale of B Medical Systems in July 2026 and collecting a related $35 million loan in September. The company has a history of reshaping itself through sales, so takeover speculation comes up from time to time, but there is no filed agreement. Its stock price reflects its own results and guidance, not an offer.
Does Azenta make a profit?
+
On a GAAP basis, not in fiscal 2026. The company lost $3.50 per share from continuing operations, mostly because of a ~$149 million non-cash goodwill impairment on its Multiomics segment taken in May 2026. Excluding that and other items, adjusted EPS was $0.48, down from $0.51 the year before, and adjusted EBITDA was ~$58 million, a 9.4% margin. The fourth quarter was stronger, with GAAP EPS of $0.14 and adjusted EPS of $0.28. Free cash flow was ~$27 million for the year. Azenta also earns interest on its cash pile, about $18 million in fiscal 2026, which supports reported earnings while operating margins stay thin. Fiscal 2027 guidance calls for higher margins and cash flow.
Who is running Azenta?
+
Dr. Martin Madaus has been interim president and CEO since August 22, 2026, when John Marotta resigned as CEO and left the board. The company said the resignation was not due to any disagreement. Madaus had been an Azenta director since January 2024 and stayed on the board; he previously led large diagnostics and lab-supply companies. His interim letter agreement sets a $600,000 base salary and a one-year performance bonus, which suggests the board expected the role to last months at least. The November 2026 earnings call did not give an update on a permanent CEO search. Shares fell about 12% the trading day after Marotta's resignation was announced, closing near $32.88.
Is there a lawsuit against Azenta?
+
Several plaintiffs' law firms, including Rosen Law Firm, Pomerantz, Kirby McInerney and Glancy Prongay Wolke and Rotter, have announced investigations into whether Azenta misled investors. Their notices point to the May 2026 guidance cut and impairment, after management had reaffirmed targets in February, and to the August 2026 CEO resignation. An investigation notice is an advertisement for clients, not a lawsuit. As of Rosen's November 8, 2026 notice, the firm still described the matter as an investigation, and no filed securities class action had been publicly confirmed. Azenta's last quarterly report, filed in August 2026, did not disclose one. A complaint could still be filed, and anyone tracking the stock may want to watch the company's next annual report.
What are Elegen and SynPlexity, and why did Azenta buy into them?
+
Both deals, announced October 30, 2026, add gene synthesis capacity to GENEWIZ. Elegen developed a cell-free method for making long, accurate DNA. Azenta licensed it on an exclusive, royalty-free basis for five years, paying fixed license fees of $23 million, with an option after 12 to 18 months to make the license perpetual for $25 million. Total spending including equipment is expected to be ~$32 million to $71 million. SynPlexity, bought outright for $15 million plus up to $10 million tied to revenue through September 2029, builds large pooled gene libraries used in drug screening. Management links both to AI-driven drug discovery, which needs many DNA designs tested quickly. They are expected to reduce fiscal 2027 margin by about 100 basis points before contributing.
How can I own Azenta, and what should I weigh?
+
Azenta trades on Nasdaq as AZTA, so you can buy whole or fractional shares at most US brokers or hold it inside a life-science tools or biotech services basket. It also appears in some small-cap and healthcare index funds at a small weight. The factors to weigh are specific: debt-free with ~$506 million of cash, but adjusted EBITDA margins near 9% against peers often above 20%; an interim CEO; a Sanger sequencing business that is shrinking; new gene synthesis bets that dilute margin first; open law-firm investigations; and a share price that rose about 20% in a day and about 34% over three months. Analysts at firms such as Needham, Jefferies, Stephens and Evercore cover the stock, and their views vary. Walnut is not an investment adviser, and this is not a recommendation.
How has AZTA stock performed in 2026?
+
AZTA closed near $44.51 on November 20, 2026, up about 33% year to date and about 48% over one year. The path was uneven: the stock traded as low as about $15.93 after the May guidance cut and impairment, fell again after the August CEO resignation, then rallied to a 52-week high near $50.06 after the November 10 fourth-quarter report. Analysts expect the next quarterly report around early February 2027.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Azenta, Inc.'s investor relations page or your broker before making investment decisions.